Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bovine Tuberculosis in Cattle: Vaccines, DIVA Tests, and Host Biomarker Discovery*

Bovine Tuberculosis in Cattle: Vaccines, DIVA Tests, and Host Biomarker Discovery* Bovine tuberculosis remains a major economic and animal welfare concern worldwide. Cattle vaccination is being considered as part of control strategies. This approach, used alongside conventional control policies, also requires the development of vaccine-compatible diagnostic assays to distinguish vaccinated from infected animals (DIVA). We discuss progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG), and on strategies to improve BCG efficacy. We also describe recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches. Finally, to accelerate vaccine development, definition of host biomarkers that provide meaningful stage-gating criteria to select vaccine candidates for further testing is highly desirable. Some progress has also been made in this area of research, and we summarize studies that defined either markers predicting vaccine success or markers that correlate with disease stage or severity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Animal Biosciences Annual Reviews

Bovine Tuberculosis in Cattle: Vaccines, DIVA Tests, and Host Biomarker Discovery*

Loading next page...
 
/lp/annual-reviews/bovine-tuberculosis-in-cattle-vaccines-diva-tests-and-host-biomarker-XULDnIbF8S

References (113)

Publisher
Annual Reviews
Copyright
Copyright 2016 Annual Reviews. All rights reserved
ISSN
2165-8102
eISSN
2165-8110
DOI
10.1146/annurev-animal-021815-111311
pmid
26884103
Publisher site
See Article on Publisher Site

Abstract

Bovine tuberculosis remains a major economic and animal welfare concern worldwide. Cattle vaccination is being considered as part of control strategies. This approach, used alongside conventional control policies, also requires the development of vaccine-compatible diagnostic assays to distinguish vaccinated from infected animals (DIVA). We discuss progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG), and on strategies to improve BCG efficacy. We also describe recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches. Finally, to accelerate vaccine development, definition of host biomarkers that provide meaningful stage-gating criteria to select vaccine candidates for further testing is highly desirable. Some progress has also been made in this area of research, and we summarize studies that defined either markers predicting vaccine success or markers that correlate with disease stage or severity.

Journal

Annual Review of Animal BiosciencesAnnual Reviews

Published: Feb 15, 2016

There are no references for this article.